#USA #New Orleans #Organoids #28bio #CNS-3D

28bio Launches CNS-3D Plasticity Organoids for Cognitive Drug Testing

In a groundbreaking announcement, 28bio has introduced its latest innovation, CNS-3D Plasticity Organoids, aimed at enhancing the drug development landscape by addressing the pressing need for effective evaluations of drug effects on human learning and memory. Traditional drug development practices have often relied on models that do not accurately predict cognitive outcomes, particularly in the realm of neurodegenerative diseases. This has led to high attrition rates, as many drug candidates fail during clinical testing phases due to insufficient predictive measures.

The Need for Improved Drug Testing

Historically, the evaluation of drug candidates focused on molecular biomarkers indicating pathology or synaptic density and semi-behavioral outputs derived from rodent maze tests. However, these approaches do not directly assess the underlying cellular processes like network potentiation and synaptic plasticity that are crucial for human learning and memory. Understanding these processes is essential as they form the foundation of cognitive functions. This is where 28bio's CNS-3D Plasticity Organoids make a significant difference.

How CNS-3D Plasticity Organoids Work

28bio's CNS-3D Plasticity Organoids consist of two human induced pluripotent stem cell (iPSC)-derived cortical organoids integrated within a custom electrode array plate that creates a connected neural network. This innovative setup allows the network to undergo training through closed-loop electrical stimulation, marking a fascinating advancement in what's being dubbed as 'organoid intelligence.' This concept is not exclusively tied to computing; its most immediate application lies in drug development, where human cell-based models that exhibit learning capabilities can reveal effects on the brain well ahead of current methodologies.

According to Thomas Hartung, MD, PhD, the Director of the Center for Alternatives to Animal Testing at Johns Hopkins University, "Organoid intelligence provides immense potential in drug development, allowing for earlier insights into cognitive impacts than ever before."

Cognitive Biomarker Assays: A New Hope

To further enhance the evaluation of drug candidates, 28bio has integrated cognitive biomarker assays into their new offerings. These assays provide two key metrics:

1. Network Potentiation Assay: This measures how well a drug candidate enhances potentiation, the critical process of strengthening neural connections associated with learning and memory.
2. Synaptic Plasticity Assay: This assesses how a drug affects reward-based learning, utilizing a virtual maze-navigation task that serves as a human neural model, paralleling traditional rodent maze-learning tests.

Corey Rountree, PhD, Lead Scientist in Functional Biology at 28bio, emphasized the significance of these assays: "Neurodegenerative and psychiatric disorders alike disrupt the synaptic mechanisms central to learning. Thus, these functional endpoints can provide invaluable insights across a spectrum of CNS-related conditions."

Availability of CNS-3D Plasticity Organoids

CNS-3D Plasticity Organoids are now accessible through 28bio's CNS-3D Services, paving the way for researchers and pharmaceutical companies to rethink drug testing approaches.

A New Era of Neurotechnology

28bio stands at the forefront of innovation within neurotechnology, seeking to engineer human brain models at scale that demonstrate memory, learning, and cognitive function. Through their Nexon™ platform, which integrates advanced tissue engineering, neural interfacing, and artificial intelligence, 28bio is on a mission to tackle the neurological health crisis and enhance the predictive capability of therapies for humans.

As they continue to strive for ethical development in the field of brain organoid technology, 28bio is poised to revolutionize how cognitive functions are studied and tested in the context of drug development, ultimately leading to more effective therapies for patients worldwide.